CANTON STRATEGIC HOLDINGS IN (CNTN) Stock Price & Overview
NASDAQ:CNTN • US4327053090
Current stock price
The current stock price of CNTN is 3.24 USD. Today CNTN is down by 0%. In the past month the price decreased by -30.77%.
CNTN Key Statistics
- Market Cap
- 166.925M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.11
- Dividend Yield
- N/A
CNTN Stock Performance
CNTN Stock Chart
CNTN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CNTN.
CNTN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTN. CNTN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CNTN Earnings
CNTN Forecast & Estimates
CNTN Groups
Sector & Classification
CNTN Financial Highlights
Over the last trailing twelve months CNTN reported a non-GAAP Earnings per Share(EPS) of -4.11. The EPS increased by 77.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -134.03% | ||
| ROE | -167.66% | ||
| Debt/Equity | 0.03 |
CNTN Ownership
CNTN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.33 | 380.121B | ||
| AMGN | AMGEN INC | 15.37 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.85 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.98 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.17 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.5 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.13 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.08 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.31 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CNTN
Company Profile
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. In addition to driving value through activities on the Canton Network, the Company operates a Super Validator, ensuring safe and secure transactions across the Network. The firm also operates a clinical-stage biotech research and development arm. Its lead clinical asset, GV104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter high-potency opioids. The expanded pipeline includes other indications for GV104 and GV023, a new approach to autoimmune diseases, as well as an early-stage multispecific biologic platform.
Company Info
IPO: 2022-01-12
CANTON STRATEGIC HOLDINGS IN
1200 Route 22 East
Bridgewater NEW JERSEY US
Employees: 2
Phone: 13026457400
CANTON STRATEGIC HOLDINGS IN / CNTN FAQ
What does CANTON STRATEGIC HOLDINGS IN do?
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. In addition to driving value through activities on the Canton Network, the Company operates a Super Validator, ensuring safe and secure transactions across the Network. The firm also operates a clinical-stage biotech research and development arm. Its lead clinical asset, GV104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter high-potency opioids. The expanded pipeline includes other indications for GV104 and GV023, a new approach to autoimmune diseases, as well as an early-stage multispecific biologic platform.
What is the stock price of CANTON STRATEGIC HOLDINGS IN today?
The current stock price of CNTN is 3.24 USD.
Does CNTN stock pay dividends?
CNTN does not pay a dividend.
What is the ChartMill technical and fundamental rating of CNTN stock?
CNTN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is CANTON STRATEGIC HOLDINGS IN (CNTN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CNTN.